Home > News > Headline News > Archive

Click on title to read the full article.

Eribulin Prolongs Survival in Women with Metastatic Breast Cancer

April 28, 2009

By Will Boggs, MD

NEW YORK (Reuters Health) - Eribulin, a nontaxane microtubule dynamics inhibitor, prolongs survival in heavily pretreated women with metastatic breast cancer, according to a report in the April Journal of Clinical Oncology.

“Eribulin is a very active drug with a good toxicity profile,” Dr. Linda T. Vahdat from Weill Cornell Medical College, New York, told Reuters Health. “It is a great drug and needs to get approved.”

Brain metastases hijack neuron-supporting cells to resist chemotherapy

April 28, 2009

By Scott Merville, University of Texas M.D. Anderson Cancer Center

DENVER ? Cancer that spreads to other organs finds a particularly inviting hideout in the brain, where these metastases are usually far harder to treat than they are in other locations. Two researchers from The University of Texas M. D. Anderson Cancer Center discussed ways to more successfully target these tumors in their “sanctuary” at the American Association for Cancer Research 100th Annual Meeting 2009 in Denver.

Professor of Cancer Biology Isaiah J. Fidler, D.V.M., Ph.D., presented a novel theory about why brain metastases are resistant to chemotherapy.

Surveyed Experts Indicate That the Combination of Sutent and Taxol Has Advantages Over the Combination of Avastin and Taxol

April 23, 2009

By Decision Resources

Sutent/Taxol Will Earn Decision Resources’ Clinical Gold Standard Status for the Indication by 2012, According to a New Report from Decision Resources

WALTHAM, Mass., — Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed oncologists identify a therapy’s effect on overall survival as the attribute that most influences their prescribing decisions in metastatic triple-negative breast cancer. Clinical data and the opinions of interviewed thought leaders indicate that Pfizer’s Sutent, in combination with Bristol-Myers Squibb’s Taxol, has advantages in this attribute over sales-leading Roche/Chugai’s Avastin and Taxol.

Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference

April 21, 2009

By Karmanos Cancer Institute

DENVER— Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit today presented data at the American Association for Cancer Research’s 100th Annual Meeting 2009 that represents significant research advancements in the treatment of the most aggressive forms of invasive breast cancer.

Karmanos researchers discovered that when an FDA-approved cancer treatment typically used to treat cutaneous T-cell lymphoma was administered before a novel experimental antitumor agent — which works best in breast cancers expressing the estrogen receptor (ER) — estrogen receptors were reinstated in receptor-negative breast cancer cells so that treatment was also effective in fighting the difficult to treat ER-negative disease

AACR: Genetic Profiling May Optimize Cancer Treatment

April 21, 2009

By Health Day News

Testing for genetic variations may allow clinicians to adjust cancer treatments that optimize progression-free survival, according to several studies presented at the 100th Annual Meeting of the American Association for Cancer Research held from April 18 to 22 in Denver.

In one study, Daniel Von Hoff, M.D., from TGen, a non-profit research institute in Phoenix, and colleagues conducted molecular profiling of 66 patients with either refractory ovarian, colorectal, breast, or miscellaneous cancer. After the results suggested a new treatment, improvements in progression-free survival were significantly higher in patients with ovarian, breast, colorectal, and miscellaneous cancer (20 percent, 36 percent, 44 percent, and 16 percent, respectively).

Pfizer Halts One Study of Sutent for Breast Cancer

April 3, 2009

By Shannon Pettypiece, Bloomberg

Pfizer Inc. said it halted one of four late-stage studies for the kidney cancer drug Sutent in patients with advanced breast cancer.

Confirmed tumor biopsies led to altered breast cancer management in patients with distant metastases

April 1, 2009

By HemOncToday

In a prospective study, biopsies revealed differences in hormone-receptor status between primary tumor and distant metastases, resulting in a change in management for 20% of patients.